ImmunityBio, Inc.
ImmunityBio is dedicated to developing innovative immunotherapies that harness the power of the human immune system to treat cancer, infectious diseases, and inflammatory diseases. The company focuses on creating targeted, personalized treatments that strengthen the immune response, aiming to reprogram the patient's immune system to fight disease effectively. They are engaged in extensive research, clinical trials, and collaborations with institutions like the National Cancer Institute to advance cancer prevention and treatment. ImmunityBio actively develops therapies such as NK-92® natural killer cell line, IL-15 superagonist Anktiva (N-803), engineered NK cell therapies, and adenovirus-vectored anti-cancer vaccines, with a focus on making these treatments more accessible and affordable globally.
Industries
Nr. of Employees
large (251-1000)
ImmunityBio, Inc.
Patents
Combined wide and deep machine learning models for automated database element processing systems, methods and apparatuses
US-12339918-B2
View DetailsContent authentication and validation via multi-factor digital tokens, systems, and methods
US-12332986-B2
View Details
Combined wide and deep machine learning models for automated database element processing systems, methods and apparatuses
US-12339918-B2
View DetailsContent authentication and validation via multi-factor digital tokens, systems, and methods
US-12332986-B2
View DetailsProducts
Standardized NK research cell line (research reagent)
A standardized NK research cell line provided as a bioanalytical tool for developing reproducible functional cytotoxicity assays and assay validation for research use.
CAR-engineered NK cell therapeutic (clinical example)
A CAR-engineered NK cell therapy developed and tested clinically for B-cell malignancies with reported complete responses in some patients, delivered as an outpatient infusion in clinical trial settings.
IL-15 superagonist immunomodulator for combination oncology therapy
An IL-15 superagonist immunomodulator developed for use in combination with local or systemic cancer therapies, with clinical data supporting activity in combination regimens and regulatory interactions in at least one jurisdiction.
Adenoviral vector-based personalized cancer vaccine platform
A vaccine development platform using adenoviral vectors integrated with neoepitope prediction to deliver patient-specific tumor antigens intended to elicit tailored anti-tumor immune responses.
Standardized NK research cell line (research reagent)
A standardized NK research cell line provided as a bioanalytical tool for developing reproducible functional cytotoxicity assays and assay validation for research use.
CAR-engineered NK cell therapeutic (clinical example)
A CAR-engineered NK cell therapy developed and tested clinically for B-cell malignancies with reported complete responses in some patients, delivered as an outpatient infusion in clinical trial settings.
IL-15 superagonist immunomodulator for combination oncology therapy
An IL-15 superagonist immunomodulator developed for use in combination with local or systemic cancer therapies, with clinical data supporting activity in combination regimens and regulatory interactions in at least one jurisdiction.
Adenoviral vector-based personalized cancer vaccine platform
A vaccine development platform using adenoviral vectors integrated with neoepitope prediction to deliver patient-specific tumor antigens intended to elicit tailored anti-tumor immune responses.
Services
Collaboration with clinical investigators and institutions to test immunotherapies in investigator-initiated and sponsor-sponsored trials, including centralized IRB review, multicenter start-up coordination and site onboarding.
Preclinical testing of combination regimens, intra-tumoral and systemic delivery studies, animal model tumor rechallenge experiments and translational assays to generate efficacy and safety data supporting clinical progression.
Clinical-scale manufacturing capacity and CMC development support for cell-based therapeutics and biologics, including process development for expansion, formulation and release testing.
End-to-end clinical molecular profiling combining whole-genome, whole-transcriptome and quantitative proteomics performed in CLIA/CAP-accredited laboratory settings to inform neoepitope selection and patient stratification for personalized therapies.
Collaboration with clinical investigators and institutions to test immunotherapies in investigator-initiated and sponsor-sponsored trials, including centralized IRB review, multicenter start-up coordination and site onboarding.
Preclinical testing of combination regimens, intra-tumoral and systemic delivery studies, animal model tumor rechallenge experiments and translational assays to generate efficacy and safety data supporting clinical progression.
Clinical-scale manufacturing capacity and CMC development support for cell-based therapeutics and biologics, including process development for expansion, formulation and release testing.
End-to-end clinical molecular profiling combining whole-genome, whole-transcriptome and quantitative proteomics performed in CLIA/CAP-accredited laboratory settings to inform neoepitope selection and patient stratification for personalized therapies.
Expertise Areas
- NK cell-based cellular immunotherapy
- Allogeneic/off-the-shelf cell therapy manufacturing and CMC
- Cancer vaccine development with neoepitope-based personalization
- Integrated multi-omics biomarker discovery and patient stratification
Key Technologies
- Standardized NK research cell lines
- Chimeric antigen receptor (CAR) engineering for NK cells
- High-affinity Fc receptor engineering
- IL-15 superagonist and cytokine-based immunomodulators
News & Updates
ImmunityBio reported complete responses in non-Hodgkin Waldenstrom lymphoma patients treated with a chemotherapy-free, first-in-class CD19 CAR-NK immunotherapy.
The Houston VA Medical Center became one of the first VA hospitals in the U.S. to provide treatment to a veteran with bladder cancer using ANKTIVA®.
ImmunityBio reported a 60% increase in revenue in Q2 2025, with year-to-date sales of approximately $43 million and 246% unit growth since J-code implementation.
ImmunityBio reported complete responses in non-Hodgkin Waldenstrom lymphoma patients treated with a chemotherapy-free, first-in-class CD19 CAR-NK immunotherapy.
The Houston VA Medical Center became one of the first VA hospitals in the U.S. to provide treatment to a veteran with bladder cancer using ANKTIVA®.
ImmunityBio reported a 60% increase in revenue in Q2 2025, with year-to-date sales of approximately $43 million and 246% unit growth since J-code implementation.